Expert Interview
What Should We Expect from NBIX's Upcoming Phase 2 T-Force GREEN Data for Ingrezza (Valbenazine NBI-98854) in Adults and Pediatrics with Tourette's?
Ticker(s): NBIXA psychiatry or neurology expert with a focus on TS and an understanding of Ingrezza.
What is your background treating TS? How many patients do you typically treat with the disease? What age range do you typically see?
Added By: kcmckee
What do you expect to see from the Phase 2 T-Force GREEN data?
What are your general thoughts on the data thus far? What are your general thoughts on the data thus far? Do you see any potential points of concern or obstacles the data raises?
What would you expect to see from the Phase 2 data based on what we’ve seen from T-FORCE? Would you expect a significant difference in how this is tolerated in adults vs children?
What are your thoughts on NBIX’s trials for SER-109 in Tardive Dyskinesia? Is this market significant? Would you expect this drug to work in these types of patients as well?
What are the biggest problems you see with current TS treatments? What do you currently use? Are there any potential or upcoming treatments you are excited about?
Do you find the science behind Valbenazine’s selective dopamine transporter inhibition compelling? Why would blocking the VMAT2 mechanism make the most sense vs others like VMAT1? Do you have concerns about the side effects this type of action mechanism could cause?
How likely do you think it is valbenazine will be approved? How quickly do you think it would make it to market? What sort of market share do you think a drug like this would receive?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
- Phase 2 T-Forward Data due in Early 2017 for Neurocrine's (NBIX) Ingrezza (Valbenazine) in Adults with Tourette Syndrome NBIX Occurred On: Jan 17, 2017
- Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Children and Adolescents with Tourette Syndrome NBIX Occurred On: Feb 02, 2016
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
